Michael J Root

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5671524/publications.pdf

Version: 2024-02-01

759233 940533 17 658 12 16 h-index citations g-index papers 17 17 17 894 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Design of a Potent <scp>d</scp> -Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance. Journal of Virology, 2010, 84, 11235-11244.	3.4	146
2	HIV-1 gp41 as a Target for Viral Entry Inhibition. Current Pharmaceutical Design, 2004, 10, 1805-1825.	1.9	91
3	Kinetic Dependence to HIV-1 Entry Inhibition. Journal of Biological Chemistry, 2006, 281, 25813-25821.	3.4	68
4	Asymmetric Deactivation of HIV-1 gp41 following Fusion Inhibitor Binding. PLoS Pathogens, 2009, 5, e1000674.	4.7	54
5	Interactions of HIV-1 Inhibitory Peptide T20 with the gp41 N-HR Coiled Coil. Journal of Biological Chemistry, 2009, 284, 3619-3627.	3.4	49
6	Mechanism of Multivalent Nanoparticle Encounter with HIV-1 for Potency Enhancement of Peptide Triazole Virus Inactivation. Journal of Biological Chemistry, 2015, 290, 529-543.	3.4	46
7	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. PLoS Pathogens, 2016, 12, e1005983.	4.7	43
8	Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5016-5021.	7.1	41
9	Evaluation of the efficiency of human immune system reconstitution in NSG mice and NSG mice containing a human HLA.A2 transgene using hematopoietic stem cells purified from different sources. Journal of Immunological Methods, 2015, 422, 13-21.	1.4	34
10	Receptor Activation of HIV-1 Env Leads to Asymmetric Exposure of the gp41 Trimer. PLoS Pathogens, 2016, 12, e1006098.	4.7	32
11	Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology, 2008, 5, 116.	2.0	22
12	Complex interplay of kinetic factors governs the synergistic properties of HIV-1 entry inhibitors. Journal of Biological Chemistry, 2017, 292, 16498-16510.	3.4	17
13	Characterization of resistance to a potent d-peptide HIV entry inhibitor. Retrovirology, 2019, 16, 28.	2.0	5
14	Site-Specific Polymer Attachment to HR2 Peptide Fusion Inhibitors against HIV-1 Decreases Binding Association Rates and Dissociation Rates Rather Than Binding Affinity. Bioconjugate Chemistry, 2017, 28, 701-712.	3.6	4
15	Altered Env conformational dynamics as a mechanism of resistance to peptide-triazole HIV-1 inactivators. Retrovirology, 2021, 18, 31.	2.0	3
16	Regulation of epitope exposure in the gp41 membrane-proximal external region through interactions at the apex of HIV-1 Env. PLoS Pathogens, 2022, 18, e1010531.	4.7	3
17	Complex interplay of kinetic factors governs the synergistic properties of HIVâ€1 entry inhibitors. FASEB Journal, 2018, 32, .	0.5	O